APOE-stratified genome-wide association study suggests potential novel genes for late-onset Alzheimer's disease in East-Asian descent

Sarang Kang^{a,b,1}, Jungsoo Gim^{a,b,c,1,*}, Tamil Iniyan Gunasekaran^{a,c}, Kyu Yeong Choi^a, Jang Jae Lee^a, Eun Hyun Seo^{a,d}, Pan-Woo Ko^e, Ji Yeon Chung^{a,f}, Seong-Min Choi^{a,g}, Young Min Lee^h, Jee Hyang Jeongⁱ, Kyung Won Park^j, Min Kyung Song^{a,k}, Ho-Won Lee^e, Ki Woong Kim^{l,m}, Seong Hye Choiⁿ, Dong Young Lee^o, Sang Yun Kim^p, Hoowon Kim^{a,f}, Byeong C. Kim^{a,g}, Takeshi Ikeuchi^q, and Kun Ho Lee^{a,b,c,r,s,*}

^aGwangju Alzheimer's & Related Dementias Cohort Research Center, Chosun University, Gwangju 61452, Republic of Korea

^bDepartment of Integrative Biological Sciences and BK21 FOUR Educational Research Group for Age-Associated Disorder Control Technology, Chosun University, Gwangju 61452, Republic of Korea

^cDepartment of Biomedical Science, Chosun University, Gwangju 61452, Republic of Korea

^dDepartment of Premedical Science, Chosun University College of Medicine, Gwangju 61452, Republic of Korea

^eDepartment of Neurology, Kyungpook National University School of Medicine, Daegu 41566, Republic of Korea

^fDepartment of Neurology, Chosun University Hospital, Gwangju 61452, Republic of Korea

^gDepartment of Neurology, Chonnam National University Medical School, Gwangju 61469, Republic of Korea

^hDepartment of Psychiatry, Pusan National University School of Medicine, Busan 50612, Republic of Korea

ⁱDepartment of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine, Seoul 07985, Republic of Korea

ⁱ*Department of Neurology, Donga University College of Medicine, Busan 49315, Republic of Korea*

^k*Chonnam National University Gwangju 2nd Geriatric Hospital, Gwangju 61469, Republic of Korea*

^l*Department of Psychiatry and Behavioral Science, Seoul National University College of Medicine, Seoul 03080, Republic of Korea*

^m*Department of Brain and Cognitive Science, Seoul National University College of Natural Sciences, Seoul 03080, Republic of Korea*

ⁿ*Department of Neurology, Inha University School of Medicine, Incheon 22212, Republic of Korea*

^o*Department of Neuropsychiatry, Seoul National University Hospital, Seoul 03080, Republic of Korea*

^p*Department of Neurology, Seoul National University Bundang Hospital, Seongnam 13620, Republic of Korea*

^q*Department of Molecular Genetics, Brain Research Institute, Niigata University, Niigata 950-2181, Japan*

^r*Korea Brain Research Institute, Daegu 41062, Republic of Korea*

^s*Neurozen Inc., Seoul 06236, Republic of Korea*

Note: [1] These authors contributed equally to this work.

Correspondence: [*] Correspondence to: Jungsoo Gim, PhD, Department of Biomedical Science, Chosun University, Gwangju 61452, Republic of Korea, Email: jgim@chosun.ac.kr and Kun Ho Lee, PhD, Department of Biomedical Science, Chosun University, Gwangju 61452, Republic of Korea, Email: leekho@chosun.ac.kr

Running title: East Asian-specific novel loci associated with LOAD

ABSTRACT

In this study, we report two new possible susceptible genes for late-onset Alzheimer's disease identified through an APOE-stratified genome-wide association analysis (GWAS) using East Asian samples. In the discovery phase, we performed a GWAS of Alzheimer's disease in 2,291 Korean seniors from the Gwangju Alzheimer's and Related Dementias (GARD) cohort study. A successive replication analysis with a Japanese sample of size 1,956 suggested three novel susceptible SNPs in two genes: *LRIG1* and *CACNA1A*. This study demonstrates that the discovery of AD-associated variants can be accomplished in non-European ethnic groups with a more homogeneous genetic background using samples comprising fewer subjects.

Keywords: Genome-wide association study (GWAS), Alzheimer's disease, Late-onset Alzheimer's disease, APOE, Stratified genome analysis

INTRODUCTION

A genetic component has consistently been identified as an important antecedent factor in Alzheimer's disease (AD), and Apolipoprotein E (*APOE*) is the most prevalent risk factor of the disease [1, 2]. The effect of the *APOE* genotype, however, varies greatly among populations [3]. One noteworthy example is that the e4 allele, the risk form of *APOE*, is virtually absent among Arabs living in the northern Israeli community where the prevalence of dementia (in spite of unspecified pathology) is roughly double that in European ancestry [4].

Since the identification of the only locus in *APOE* with a sample consisting of 1,086

individuals in 2007 [5], genome-wide association studies (GWASs) have increased the sample size to improve the statistical power to identify the missing causal variants for late-onset AD (LOAD) [6, 7]. The latest and largest GWAS expands to include 1,126,563 cases and controls (including 364,859 proxy) [Douglas P. Wightman, et al., 2020, medRxiv: <https://doi.org/10.1101/2020.11.20.20235275>]. The variants and associated genes from those GWASs were identified mostly in individuals of European ancestry and found enriched in various biological pathways, including immune responses and endocytosis, suggesting genetic heterogeneity or the complex nature of the LOAD.

Genetic studies in diverse populations have increased our understanding of the genetic architecture of LOAD [8-12]. Studies of non-European ancestry populations might have a chance of being used to discover variants that are rare or absent, thus showing a smaller effect size in European ancestry [13]. Notably, the discovery of such AD-susceptible loci, displaying allelic heterogeneity among diverse populations, has been accomplished with non-European ancestry groups of a more homogeneous genetic background using samples comprising several thousand or much fewer subjects [10, 11].

In the present study, we leverage the genetic architecture of Koreans, a homogeneous East Asian population maintaining a distinct genetic profile with a high prevalence of AD among seniors (65 years and older), to discover AD-associated variants. For this purpose, we first performed GWAS and post-hoc GWAS with APOE stratified in Koreans using the Korea Biobank Array (referred to as Korean Chip) designed for Koreans [14] and replicated the findings by combining genotype level data from

another East Asian population [11].

MATERIALS AND METHODS

Study Sample

We analyzed genotype level data of 2,291 individuals (1,119 AD cases and 1,172 controls) for the discovery stage, and 1,956 individuals (980 AD cases and 976 controls) for the replication stage (**Table 1**). Participants for the discovery stage were sampled from the Gwangju Alzheimer's & Related Dementias (GARD) Cohort Research Center, a longitudinal single-center study designed to develop clinical, imaging, genetic, and other biomarkers for early detection and tracking of dementia (mostly AD) from local senior citizens aged 60 years or older in Gwangju, South Korea. The study protocol was approved by the Institutional Review Board of Chosun University Hospital, Korea (CHOSUN 2013-12-018-070). All volunteers or authorized guardians for cognitively impaired individuals gave written informed consent before participation. Out of 16,002 participants in the GARD cohort, 2,291 (1,119 AD dementia and 1,172 cognitive normal) were chosen to maximize contrast between AD cases and cognitive normal controls for the GWAS. All cases were at least 60 years old and met NINCDS-ADRDA criteria for AD [15], while cognitively healthy controls were at least 70 years old and either judged to be cognitively normal or did not meet pathological criteria (**Supplementary Material**).

Genotyping, Imputation, and Gene Mapping

We applied extensive quality control measures used in the standard protocol [16] and

excluded subjects with a low genotyping success rate (95%), heterozygosity outliers and those that exhibited cryptic relatedness. We assessed study population heterogeneity by means of a principal component analysis (PCA) and multidimensional scaling (MDS) and removed those that did not meet the criteria before proceeding with further analyses. We also excluded those with SNPs with a minor allele frequency <1%, a genotyping success rate <95%, or a deviation of the genotype distribution from Hardy-Weinberg equilibrium in the control group ($P < 1 \times 10^{-6}$). To increase the genotyping coverage between the two datasets, we imputed missing genotypes and SNPs using pre-phased reference haplotypes from the Haplotype Reference Consortium (HRC) panel version 1.1 for each dataset. We subjected all imputed SNPs to the same quality criteria described above and added the requirement of imputation quality with an info score >0.5, leaving 35,685,761 and 39,044,005 SNPs for discovery and replication analysis, respectively. Functional mapping of SNPs to genes was conducted using a gene annotation file from Affymetrix [14] and the SNPnexus web tool [17].

Statistical analysis

A set of GWAS analyses for AD status was performed in three models of a two-stage framework (discovery and replication): 1) all samples; 2) APOE e4 carriers; and 3) APOE e4 non-carriers. The GWAS was performed separately in each model for both the discovery and replication stages. The association of genotype dosages of each SNP in the additive component with the AD case-control status was estimated using logistic regression analysis adjusting for age, sex, and first four principal components using PLINK and EIGENSTRAT software [18-20]. Only the SNPs that attained a

suggestively significant association level ($P < 5 \times 10^{-5}$) were tested in the replication stage using a Japanese dataset. A total of 4,247 subjects was assembled for meta-analysis and SNP effect estimates and their SEs were combined by a fixed effect model with inverse variance weighted method using the METAL software [21]. SNP heritability was estimated using the GCTA software [22].

RESULTS

Genome-wide inference for AD status

For discovery, we first conducted GWA analysis with the GARD sample, which included 2,291 subjects and identified 54 genome-wide significant (5×10^{-8}) SNPs across three genes (genomic inflation = 1.03), and all those genes (*APOE*, *PVRL2*, and *TOMM40*) were found to be associated with LOAD in previous studies (**Table 2**). We estimated the liability-scale SNP heritability, excluding those loci, and a relatively large estimate (0.566 ± 0.152) was obtained. In addition, a portion of SNPs in other previously known genes, such as *ABCA7* and *BIN1*, was replicated at a genome-wide suggestive level (5×10^{-5}). These results suggest that additional common variants with smaller effects (or possibly rarer variants with larger effects) yet to be found might be identified through a post-hoc analysis with a less stringent statistical significance.

We carried out *APOE*-stratified GWA analysis using subgroups of *APOE* e4 carrying status. A total of 219 variants (annotated in 61 genes) and 306 variants (in 82 genes) were respectively identified as e4 carriers (genomic inflation = 1.02) and non-carriers (genomic inflation = 1.03) with a suggestive level of 5×10^{-5} . Loosening statistical

significance might increase false findings; thus, we included an independent cohort dataset for replication. For valid novel discovery, we performed a meta-analysis with the replication dataset, filtered with previous GWAS signals, resulting in examination of 7 out of 61 and 15 out of 82 genes for e4 carriers and non-carriers, respectively. Considering the effect direction and statistical significance of the variants in both the discovery and replication datasets, *CACNA1A* (OR = 1.726, lead SNP rs189753894) and *LRIG1* (OR = 0.539, lead SNP rs2280575) remained in the association result for further functional annotation (**Table 2**).

Functional annotation

We followed up the association results of two novel genes, *CACNA1A* and *LRIG1*, by carrying out functional annotation using web-based platforms from the Human Protein Atlas (HPA) [23], Genotype-Tissue Expression (GTEx) [24], and Functional Annotation of Mammalian Genomes 5 (FANTOM5) [25]. *CACNA1A*, a risk gene candidate, is on chromosome 19. However, it is not likely to be influenced by the *APOE* signal because *CACNA1A* is far from the *APOE* locus (more than 32Mb) and is identified with *APOE* non-carriers. We also confirmed its independence with all subjects by conditional analysis with *APOE**4 (rs429358). Tissue specificity analysis with GTEx, FANTOM5, and HPA showed that *CACNA1A* is expressed in brain tissues, particularly in the cerebellum at both the transcription and protein levels (**Supplementary Fig. 1A, Fig. 1A**). The *CACNA1A* gene plays an important role in neuronal cell death. It codes subunits of neuronal calcium channels, which are involved in the neuronal cell death and toxicity of amyloid beta [26, 27].

Expression levels of *LRIG1* were high in the cerebral cortex at 74.1 protein-coding

transcripts per million (pTPM) in HPA, 16.0 pTPM reported by GTEx (**Supplementary Fig. 1B**). In the FANTOM5 dataset, the RNA expression levels of *LRIG1* were higher in the brain tissues than in other tissues, especially for the hippocampal formation, which was 179.9 scaled tags per million. eQTL analysis with lead SNP rs2280575 in *LRIG1* showed significant results in the hypothalamus (**Fig. 1B**). The association between *LRIG1* and the hippocampus was evaluated in *in vitro* and *in vivo* analyses in a previous study [28].

DISCUSSION

Here, we conducted GWA analysis with a Korean sample to identify AD-associated loci. We validated the association between AD status and *APOE* locus in chromosome 19 with genome-wide significance. To mask the effect of *APOE* and identify novel candidate loci in East Asians, we carried out an *APOE4* stratified GWAS with two independent East Asian samples and identified *CACNA1A* (lead SNP rs189753894) and *LRIG1* (lead SNP rs2280575) among *APOE4* non-carriers.

From the functional annotation and literature survey, we found that the two genes play an essential role in neurobiological function. *CACNA1A*, a subunit of the neuronal calcium channel, is predominantly and specifically expressed in brain tissue and was found to be involved in neuronal cell death and toxicity of amyloid beta, suggesting a plausible risk gene for AD. The genetic function of *LRIG1* has been shown to be involved in the dendritic formation of neurons, as well as in affecting the neural cell function of the hippocampus. Abnormal expression and dysfunction of *LRIG1* lead to dendritic abnormalities, which are involved in morphogenesis of hippocampal

dendrites by brain-derived neurotrophic factor (BDNF) signaling. BDNF plays a major role in the growth, development and survival of neurons, and is involved in synaptic plasticity and synaptogenesis for learning and memory in the adult brain [29-31]. BDNF showed low gene expression levels in patients with AD [32]. Several studies have shown that high expression levels of BDNF could slow down cognitive decline in the elderly and in patients with AD [29, 33-35].

There are limitations to this study that need to be considered. The sample size in this study is relatively smaller than those in other AD GWA studies. However, the sample used in this analysis was a representative sample with well-defined cases and controls: subjects to maximize contrast were chosen, and any subjects with ambiguous diagnosis were removed from the further analysis. Although the previous studies about the function of *CACNA1A* and *LRIG1* suggest their role in the development of the LOAD, a conclusion whether each gene has an impact on the progression of dementia or protecting neurons from degeneration requires further biological validation with an AD model system.

To conclude from the findings made in this work, we validated a portion of previously reported LOAD-associated genes, identified from the mostly Caucasian subjects, using the Koreans. We also identified and replicated East Asian-specific novel loci in *CACNA1A* and *LRIG1* through a post-hoc GWAS with APOE4 stratified. The finding in this work might provide an improved understanding of complex genetic signature of LOAD.

Acknowledgments This research was supported by the Original Technology Research Program for Brain Science of the National Research Foundation (NRF-2014M3C7A1046041 and NRF-2014M3C7A1046042), and KBRI basic research program (20-BR-03-02) funded by Koera Ministry of Science and ICT. This study was also supported by Japan Agency for Medical Research and Development (AMED) (JP18kk0205009).

IRB The study protocol was approved by the Institutional Review Board of Chosun University Hospital, Korea (CHOSUN 2013-12-018-070). All volunteers or authorized guardians for cognitively impaired individuals gave written informed consent before participation.

Conflict of Interest/Disclosure Statement The authors have no conflict of interest to report

REFERENCES

- [1] Farrer LA, Myers RH, Connor L, Cupples LA, Growdon JH (1991) Segregation analysis reveals evidence of a major gene for Alzheimer disease. *Am J Hum Genet* **48**, 1026-1033.
- [2] Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD (1993) Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. *Proc Natl Acad Sci U S A* **90**, 8098-8102.
- [3] Singh PP, Singh M, Mastana SS (2006) APOE distribution in world populations with new data from India and the UK. *Ann Hum Biol* **33**, 279-308.
- [4] Sherva R, Baldwin CT, Inzelberg R, Vardarajan B, Cupples LA, Lunetta K, Bowirrat A, Naj A, Pericak-Vance M, Friedland RP, Farrer LA (2011) Identification of novel candidate genes for Alzheimer's disease by autozygosity mapping using genome wide SNP data. *J Alzheimers Dis* **23**, 349-359.
- [5] Coon KD MA, Craig DW, Webster JA, Pearson JV, Lince DH, Zismann VL, Beach TG, Leung D, Bryden L, Halperin RF, Marlowe L, Kaleem M, Walker DG, Ravid R, Heward CB, Rogers J, Papassotiropoulos A, Reiman EM, Hardy J, Stephan DA. (2007) A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. *J Clin Psychiatry* **68**, 613-618.
- [6] Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, Boland A, Vronskaya M, van der Lee SJ, Amlie-Wolf A, Bellenguez C, Frizatti A, Chouraki V, Martin ER, Sleegers K, Badarinarayan N, Jakobsdottir J, Hamilton-Nelson KL, Moreno-Grau S, Olsas R, Raybould R, Chen Y, Kuzma AB, Hiltunen M, Morgan T, Ahmad S, Vardarajan BN, Epelbaum J, Hoffmann P, Boada M, Beecham GW, Garnier JG, Harold D, Fitzpatrick AL, Valladares O, Moutet ML, Gerrish A, Smith AV, Qu L, Bacq D, Denning N, Jian X, Zhao Y, Del Zompo M, Fox NC, Choi SH, Mateo I, Hughes JT, Adams HH, Malamon J, Sanchez-Garcia F, Patel Y, Brody JA, Dombroski BA, Naranjo MCD, Daniilidou M, Eiriksdottir G, Mukherjee S, Wallon D, Uphill J, Aspelund T, Cantwell LB, Garzia F, Galimberti D, Hofer E, Butkiewicz M, Fin B, Scarpini E, Sarnowski C, Bush WS, Meslage S, Kornhuber J, White CC, Song Y, Barber RC, Engelborghs S, Sordon S, Voijnovic D, Adams PM, Vandenberghe R, Mayhaus M, Cupples LA, Albert MS, De Deyn PP, Gu W, Himali JJ, Beekly D, Squassina A, Hartmann AM, Orellana A, Blacker D, Rodriguez-Rodriguez E, Lovestone S, Garcia ME, Doody RS, Munoz-Fernandez C, Sussams R, Lin H, Fairchild TJ, Benito YA, Holmes C, Karamujic-Comic H, Frosch MP, Thonberg H, Maier W, Roshchupkin G, Ghetti B, Giedraitis V, Kawalia A, Li S, Huebinger RM, Kilander L, Moebus S, Hernandez I, Kamboh MI, Brundin R, Turton J, Yang Q, Katz MJ, Concar L, Lord J, Beiser AS, Keene CD, Helisalmi S, Kloszewska I, Kukull WA, Koivisto AM, Lynch A, Tarraga L, Larson EB, Haapasalo A, Lawlor B, Mosley TH, Lipton RB, Solfrizzi V, Gill M, Longstreth WT, Jr,

Montine TJ, Frisardi V, Diez-Fairen M, Rivadeneira F, Petersen RC, Deramecourt V, Alvarez I, Salani F, Ciaramella A, Boerwinkle E, Reiman EM, Fievet N, Rotter JI, Reisch JS, Hanon O, Cupidi C, Andre Uitterlinden AG, Royall DR, Dufouil C, Maletta RG, de Rojas I, Sano M, Brice A, Cecchetti R, George-Hyslop PS, Ritchie K, Tsolaki M, Tsuang DW, Dubois B, Craig D, Wu CK, Soininen H, Avramidou D, Albin RL, Fratiglioni L, Germanou A, Apostolova LG, Keller L, Koutroumani M, Arnold SE, Panza F, Gkatzima O, Asthana S, Hannequin D, Whitehead P, Atwood CS, Caffarra P, Hampel H, Quintela I, Carracedo A, Lannfelt L, Rubinsztein DC, Barnes LL, Pasquier F, Frolich L, Barral S, McGuinness B, Beach TG, Johnston JA, Becker JT, Passmore P, Bigio EH, Schott JM, Bird TD, Warren JD, Boeve BF, Lupton MK, Bowen JD, Proitsi P, Boxer A, Powell JF, Burke JR, Kauwe JSK, Burns JM, Mancuso M, Buxbaum JD, Bonuccelli U, Cairns NJ, McQuillin A, Cao C, Livingston G, Carlson CS, Bass NJ, Carlsson CM, Hardy J, Carney RM, Bras J, Carrasquillo MM, Guerreiro R, Allen M, Chui HC, Fisher E, Masullo C, Crocco EA, DeCarli C, Bisceglia G, Dick M, Ma L, Duara R, Graff-Radford NR, Evans DA, Hodges A, Faber KM, Scherer M, Fallon KB, Riemenschneider M, Fardo DW, Heun R, Farlow MR, Kolsch H, Ferris S, Leber M, Foroud TM, Heuser I, Galasko DR, Giegling I, Gearing M, Hull M, Geschwind DH, Gilbert JR, Morris J, Green RC, Mayo K, Growdon JH, Feulner T, Hamilton RL, Harrell LE, Drichel D, Honig LS, Cushion TD, Huentelman MJ, Hollingworth P, Hulette CM, Hyman BT, Marshall R, Jarvik GP, Meggy A, Abner E, Menzies GE, Jin LW, Leonenko G, Real LM, Jun GR, Baldwin CT, Grozeva D, Karydas A, Russo G, Kaye JA, Kim R, Jessen F, Kowall NW, Vellas B, Kramer JH, Vardy E, LaFerla FM, Jockel KH, Lah JJ, Dichgans M, Leverenz JB, Mann D, Levey AI, Pickering-Brown S, Lieberman AP, Klopp N, Lunetta KL, Wichmann HE, Lyketsos CG, Morgan K, Marson DC, Brown K, Martiniuk F, Medway C, Mash DC, Nothen MM, Masliah E, Hooper NM, McCormick WC, Daniele A, McCurry SM, Bayer A, McDavid AN, Gallacher J, McKee AC, van den Bussche H, Mesulam M, Brayne C, Miller BL, Riedel-Heller S, Miller CA, Miller JW, Al-Chalabi A, Morris JC, Shaw CE, Myers AJ, Wiltfang J, O'Bryant S, Olichney JM, Alvarez V, Parisi JE, Singleton AB, Paulson HL, Collinge J, Perry WR, Mead S, Peskind E, Cribbs DH, Rossor M, Pierce A, Ryan NS, Poon WW, Nacmias B, Potter H, Sorbi S, Quinn JF, Sacchinelli E, Raj A, Spalletta G, Raskind M, Caltagirone C, Bossu P, Orfei MD, Reisberg B, Clarke R, Reitz C, Smith AD, Ringman JM, Warden D, Roberson ED, Wilcock G, Rogaeva E, Bruni AC, Rosen HJ, Gallo M, Rosenberg RN, Ben-Shlomo Y, Sager MA, Mecocci P, Saykin AJ, Pastor P, Cuccaro ML, Vance JM, Schneider JA, Schneider LS, Slifer S, Seeley WW, Smith AG, Sonnen JA, Spina S, Stern RA, Swerdlow RH, Tang M, Tanzi RE, Trojanowski JQ, Troncoso JC, Van Deerlin VM, Van Eldik LJ, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Wilhelmsen KC, Williamson J, Wingo TS, Woltjer RL, Wright CB, Yu CE, Yu L, Saba Y, Pilotto A, Bullido MJ, Peters O, Crane PK, Bennett D, Bosco P, Coto E, Boccardi V, De Jager PL, Lleo A, Warner N, Lopez OL, Ingelsson M, Deloukas P, Cruchaga C, Graff C, Gwilliam R, Fornage M, Goate AM, Sanchez-Juan P, Kehoe PG, Amin N, Ertekin-Taner N, Berr C, Debette S, Love

- S, Launer LJ, Younkin SG, Dartigues JF, Corcoran C, Ikram MA, Dickson DW, Nicolas G, Champion D, Tschanz J, Schmidt H, Hakonarson H, Clarimon J, Munger R, Schmidt R, Farrer LA, Van Broeckhoven C, M COD, DeStefano AL, Jones L, Haines JL, Deleuze JF, Owen MJ, Gudnason V, Mayeux R, Escott-Price V, Psaty BM, Ramirez A, Wang LS, Ruiz A, van Duijn CM, Holmans PA, Seshadri S, Williams J, Amouyel P, Schellenberg GD, Lambert JC, Pericak-Vance MA, Alzheimer Disease Genetics C, European Alzheimer's Disease I, Cohorts for H, Aging Research in Genomic Epidemiology C, Genetic, Environmental Risk in Ad/Defining Genetic P, Environmental Risk for Alzheimer's Disease C (2019) Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. *Nat Genet* **51**, 414-430.
- [7] Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S, Sealock J, Karlsson IK, Hagg S, Athanasiu L, Voyle N, Proitsi P, Witoelar A, Stringer S, Aarsland D, Almdahl IS, Andersen F, Bergh S, Bettella F, Bjornsson S, Braekhus A, Brathen G, de Leeuw C, Desikan RS, Djurovic S, Dumitrescu L, Fladby T, Hohman TJ, Jonsson PV, Kiddle SJ, Rongve A, Saltvedt I, Sando SB, Selbaek G, Shoai M, Skene NG, Snaedal J, Stordal E, Ulstein ID, Wang Y, White LR, Hardy J, Hjerling-Leffler J, Sullivan PF, van der Flier WM, Dobson R, Davis LK, Stefansson H, Stefansson K, Pedersen NL, Ripke S, Andreassen OA, Posthuma D (2019) Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. *Nat Genet* **51**, 404-413.
- [8] Ghani M, Reitz C, Cheng R, Vardarajan BN, Jun G, Sato C, Naj A, Rajbhandary R, Wang LS, Valladares O, Lin CF, Larson EB, Graff-Radford NR, Evans D, De Jager PL, Crane PK, Buxbaum JD, Murrell JR, Raj T, Ertekin-Taner N, Logue M, Baldwin CT, Green RC, Barnes LL, Cantwell LB, Fallin MD, Go RC, Griffith PA, Obisesan TO, Manly JJ, Lunetta KL, Kamboh MI, Lopez OL, Bennett DA, Hendrie H, Hall KS, Goate AM, Byrd GS, Kukull WA, Foroud TM, Haines JL, Farrer LA, Pericak-Vance MA, Lee JH, Schellenberg GD, St George-Hyslop P, Mayeux R, Rogaeva E, Alzheimer's Disease Genetics C (2015) Association of Long Runs of Homozygosity With Alzheimer Disease Among African American Individuals. *JAMA Neurol* **72**, 1313-1323.
- [9] Jun GR, Chung J, Mez J, Barber R, Beecham GW, Bennett DA, Buxbaum JD, Byrd GS, Carrasquillo MM, Crane PK, Cruchaga C, De Jager P, Ertekin-Taner N, Evans D, Fallin MD, Foroud TM, Friedland RP, Goate AM, Graff-Radford NR, Hendrie H, Hall KS, Hamilton-Nelson KL, Inzelberg R, Kamboh MI, Kauwe JSK, Kukull WA, Kunkle BW, Kuwano R, Larson EB, Logue MW, Manly JJ, Martin ER, Montine TJ, Mukherjee S, Naj A, Reiman EM, Reitz C, Sherva R, St George-Hyslop PH, Thornton T, Younkin SG, Vardarajan BN, Wang LS, Wendlund JR, Winslow AR, Alzheimer's Disease Genetics C, Haines J, Mayeux R, Pericak-Vance MA, Schellenberg G, Lunetta KL, Farrer LA (2017) Transethnic genome-wide scan identifies novel Alzheimer's disease loci. *Alzheimers Dement* **13**, 727-738.
- [10] Meng Y, Baldwin CT, Bowirrat A, Waraska K, Inzelberg R, Friedland RP, Farrer LA (2006)

- Association of polymorphisms in the Angiotensin-converting enzyme gene with Alzheimer disease in an Israeli Arab community. *Am J Hum Genet* **78**, 871-877.
- [11] Miyashita A, Koike A, Jun G, Wang LS, Takahashi S, Matsubara E, Kawarabayashi T, Shoji M, Tomita N, Arai H, Asada T, Harigaya Y, Ikeda M, Amari M, Hanyu H, Higuchi S, Ikeuchi T, Nishizawa M, Suga M, Kawase Y, Akatsu H, Kosaka K, Yamamoto T, Imagawa M, Hamaguchi T, Yamada M, Morihara T, Takeda M, Takao T, Nakata K, Fujisawa Y, Sasaki K, Watanabe K, Nakashima K, Urakami K, Ooya T, Takahashi M, Yuzuriha T, Serikawa K, Yoshimoto S, Nakagawa R, Kim JW, Ki CS, Won HH, Na DL, Seo SW, Mook-Jung I, Alzheimer Disease Genetics C, St George-Hyslop P, Mayeux R, Haines JL, Pericak-Vance MA, Yoshida M, Nishida N, Tokunaga K, Yamamoto K, Tsuji S, Kanazawa I, Ihara Y, Schellenberg GD, Farrer LA, Kuwano R (2013) SORL1 is genetically associated with late-onset Alzheimer's disease in Japanese, Koreans and Caucasians. *PLoS One* **8**, e58618.
- [12] Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, Katayama T, Baldwin CT, Cheng R, Hasegawa H, Chen F, Shibata N, Lunetta KL, Pardossi-Piquard R, Bohm C, Wakutani Y, Cupples LA, Cuenco KT, Green RC, Pinessi L, Rainero I, Sorbi S, Bruni A, Duara R, Friedland RP, Inzelberg R, Hampe W, Bujo H, Song YQ, Andersen OM, Willnow TE, Graff-Radford N, Petersen RC, Dickson D, Der SD, Fraser PE, Schmitt-Ulms G, Younkin S, Mayeux R, Farrer LA, St George-Hyslop P (2007) The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. *Nat Genet* **39**, 168-177.
- [13] Kunkle BW, Schmidt M, Klein HU, Naj AC, Hamilton-Nelson KL, Larson EB, Evans DA, De Jager PL, Crane PK, Buxbaum JD, Ertekin-Taner N, Barnes LL, Fallin MD, Manly JJ, Go RCP, Obisesan TO, Kamboh MI, Bennett DA, Hall KS, Goate AM, Foroud TM, Martin ER, Wang LS, Byrd GS, Farrer LA, Haines JL, Schellenberg GD, Mayeux R, Pericak-Vance MA, Reitz C, Writing Group for the Alzheimer's Disease Genetics C, Graff-Radford NR, Martinez I, Ayodele T, Logue MW, Cantwell LB, Jean-Francois M, Kuzma AB, Adams LD, Vance JM, Cuccaro ML, Chung J, Mez J, Lunetta KL, Jun GR, Lopez OL, Hendrie HC, Reiman EM, Kowall NW, Leverenz JB, Small SA, Levey AI, Golde TE, Saykin AJ, Starks TD, Albert MS, Hyman BT, Petersen RC, Sano M, Wisniewski T, Vassar R, Kaye JA, Henderson VW, DeCarli C, LaFerla FM, Brewer JB, Miller BL, Swerdlow RH, Van Eldik LJ, Paulson HL, Trojanowski JQ, Chui HC, Rosenberg RN, Craft S, Grabowski TJ, Asthana S, Morris JC, Strittmatter SM, Kukull WA (2021) Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel: A Meta-analysis. *JAMA Neurol* **78**, 102-113.
- [14] Moon S, Kim YJ, Han S, Hwang MY, Shin DM, Park MY, Lu Y, Yoon K, Jang HM, Kim YK, Park TJ, Song DS, Park JK, Lee JE, Kim BJ (2019) The Korea Biobank Array: Design and Identification of Coding Variants Associated with Blood Biochemical Traits. *Sci Rep* **9**, 1382.
- [15] McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (2011) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS--ADRDA Work Group under the

- auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology* **77**, 333-333.
- [16] Anderson CA, Pettersson FH, Clarke GM, Cardon LR, Morris AP, Zondervan KT (2010) Data quality control in genetic case-control association studies. *Nat Protoc* **5**, 1564-1573.
 - [17] Dayem Ullah AZ, Oscanova J, Wang J, Nagano A, Lemoine NR, Chelala C (2018) SNPnexus: assessing the functional relevance of genetic variation to facilitate the promise of precision medicine. *Nucleic Acids Res* **46**, W109-W113.
 - [18] Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* **81**, 559-575.
 - [19] Patterson N, Price AL, Reich D (2006) Population structure and eigenanalysis. *PLoS Genet* **2**, e190.
 - [20] Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D (2006) Principal components analysis corrects for stratification in genome-wide association studies. *Nat Genet* **38**, 904-909.
 - [21] Willer CJ, Li Y, Abecasis GR (2010) METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190-2191.
 - [22] Yang J, Lee SH, Goddard ME, Visscher PM (2011) GCTA: a tool for genome-wide complex trait analysis. *Am J Hum Genet* **88**, 76-82.
 - [23] Pontén F, Jirström K, Uhlen MJTJoPAJotPSoGB, Ireland (2008) The Human Protein Atlas—a tool for pathology. **216**, 387-393.
 - [24] Science GCJ (2015) The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans. **348**, 648-660.
 - [25] Lizio M, Abugessaisa I, Noguchi S, Kondo A, Hasegawa A, Hon CC, de Hoon M, Severin J, Oki S, Hayashizaki Y, Carninci P, Kasukawa T, Kawaji H (2018) Update of the FANTOM web resource: expansion to provide additional transcriptome atlases. *Nucleic Acids Research* **47**, D752-D758.
 - [26] Supnet C, Bezprozvanny I (2010) The dysregulation of intracellular calcium in Alzheimer disease. *Cell Calcium* **47**, 183-189.
 - [27] Demuro A, Parker I, Stutzmann GE (2010) Calcium signaling and amyloid toxicity in Alzheimer disease. *J Biol Chem* **285**, 12463-12468.
 - [28] Alsina FC, Hita FJ, Fontanet PA, Irala D, Hedman H, Ledda F, Paratcha G (2016) Lrig1 is a cell-intrinsic modulator of hippocampal dendrite complexity and BDNF signaling. *EMBO Rep* **17**, 601-616.
 - [29] Lu B, Nagappan G, Guan X, Nathan PJ, Wren P (2013) BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. *Nat Rev Neurosci* **14**, 401-416.
 - [30] Lu B, Nagappan G, Lu Y (2014) BDNF and synaptic plasticity, cognitive function, and

- dysfunction. *Handb Exp Pharmacol* **220**, 223-250.
- [31] Bramham CR, Messaoudi E (2005) BDNF function in adult synaptic plasticity: the synaptic consolidation hypothesis. *Prog Neurobiol* **76**, 99-125.
 - [32] Ng TKS, Ho CSH, Tam WWS, Kua EH, Ho RC (2019) Decreased Serum Brain-Derived Neurotrophic Factor (BDNF) Levels in Patients with Alzheimer's Disease (AD): A Systematic Review and Meta-Analysis. *Int J Mol Sci* **20**.
 - [33] Buchman AS, Yu L, Boyle PA, Schneider JA, De Jager PL, Bennett DA (2016) Higher brain *BDNF* gene expression is associated with slower cognitive decline in older adults. **86**, 735-741.
 - [34] Laske C, Stellos K, Hoffmann N, Stransky E, Straten G, Eschweiler GW, Leyhe T (2011) Higher BDNF serum levels predict slower cognitive decline in Alzheimer's disease patients. *Int J Neuropsychopharmacol* **14**, 399-404.
 - [35] Jiao SS, Shen LL, Zhu C, Bu XL, Liu YH, Liu CH, Yao XQ, Zhang LL, Zhou HD, Walker DG, Tan J, Gotz J, Zhou XF, Wang YJ (2016) Brain-derived neurotrophic factor protects against tau-related neurodegeneration of Alzheimer's disease. *Transl Psychiatry* **6**, e907.
 - [36] Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, DeStafano AL, Bis JC, Beecham GW, Grenier-Boley B, Russo G, Thorton-Wells TA, Jones N, Smith AV, Chouraki V, Thomas C, Ikram MA, Zelenika D, Vardarajan BN, Kamatani Y, Lin CF, Gerrish A, Schmidt H, Kunkle B, Dunstan ML, Ruiz A, Bihoreau MT, Choi SH, Reitz C, Pasquier F, Cruchaga C, Craig D, Amin N, Berr C, Lopez OL, De Jager PL, Deramecourt V, Johnston JA, Evans D, Lovestone S, Letenneur L, Moron FJ, Rubinsztein DC, Eiriksdottir G, Sleegers K, Goate AM, Fievet N, Huentelman MW, Gill M, Brown K, Kamboh MI, Keller L, Barberger-Gateau P, McGuinness B, Larson EB, Green R, Myers AJ, Dufouil C, Todd S, Wallon D, Love S, Rogaeva E, Gallacher J, St George-Hyslop P, Clarimon J, Lleo A, Bayer A, Tsuang DW, Yu L, Tsolaki M, Bossu P, Spalletta G, Proitsi P, Collinge J, Sorbi S, Sanchez-Garcia F, Fox NC, Hardy J, Deniz Naranjo MC, Bosco P, Clarke R, Brayne C, Galimberti D, Mancuso M, Matthews F, European Alzheimer's Disease I, Genetic, Environmental Risk in Alzheimer's D, Alzheimer's Disease Genetic C, Cohorts for H, Aging Research in Genomic E, Moebus S, Mecocci P, Del Zompo M, Maier W, Hampel H, Pilotto A, Bullido M, Panza F, Caffarra P, Nacmias B, Gilbert JR, Mayhaus M, Lannefelt L, Hakonarson H, Pichler S, Carrasquillo MM, Ingelsson M, Beekly D, Alvarez V, Zou F, Valladares O, Younkin SG, Coto E, Hamilton-Nelson KL, Gu W, Razquin C, Pastor P, Mateo I, Owen MJ, Faber KM, Jonsson PV, Combarros O, O'Donovan MC, Cantwell LB, Soininen H, Blacker D, Mead S, Mosley TH, Jr., Bennett DA, Harris TB, Fratiglioni L, Holmes C, de Bruijn RF, Passmore P, Montine TJ, Bettens K, Rotter JI, Brice A, Morgan K, Foroud TM, Kukull WA, Hannequin D, Powell JF, Nalls MA, Ritchie K, Lunetta KL, Kauwe JS, Boerwinkle E, Riemenschneider M, Boada M, Hiltunen M, Martin ER, Schmidt R, Rujescu D, Wang LS, Dartigues JF, Mayeux R, Tzourio C, Hofman A, Nothen MM, Graff C, Psaty BM, Jones L,

- Haines JL, Holmans PA, Lathrop M, Pericak-Vance MA, Launer LJ, Farrer LA, van Duijn CM, Van Broeckhoven C, Moskvina V, Seshadri S, Williams J, Schellenberg GD, Amouyel P (2013) Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nat Genet* **45**, 1452-1458.
- [37] Phan L, Jin Y, Zhang H, Qiang W, Shekhtman E, Shao D, Revoe D, Villamarin R, Ivanchenko E, Kimura MJNCfBI, US National Library of Medicine. Available online: www.ncbi.nlm.nih.gov/snp/docs/gsr/alfa/ (2020) ALFA: Allele Frequency Aggregator.

FIGURE LEGENDS AND TABLES

Table 1. Summary of demographic information of each group in GWAS analyses.

Table 2. Top-ranked genome-wide association results in the Korean discovery sample ($P < 5 \times 10^{-5}$) and their replication in Japanese and meta-analyses.

Figure 1. Gene expression of *CACNA1A* across different tissues (B) and expression quantitative trait loci (eQTL) analysis of rs2280575 in *LRIG1* (A). (A) The *CACNA1A* is expressed at a high level in the cerebellum (median TPM: 304.8) and in the cerebellar hemisphere (median TPM: 275.0). (B) Violin plot showing the effect of the eQTL rs2280575 on *LRIG1* expression in hypothalamus ($P = 1.13 \times 10^{-2}$). (Image available from <https://gtexportal.org/home/gene/CACNA1A>).

FIGURES & TABLES

Table 1. Summary of demographic information for each group in GWAS analyses

	Discovery (n=2,291)		Replication (n=1,956)	
	CN	AD	CN	AD
All samples, n	1,172	1,119	976	980
Female, n (%)	661 (56.4)	715 (63.9)	564 (57.8)	702 (71.6)
Age, m (s.d)	76.03 (8.9)	74.60 (8.9)	76.94 (5.9)	72.99 (4.3)
APOE e4 non-carrier, n	976	621	815	435
Female, n (%)	544 (55.7)	393 (63.3)	470 (57.7)	31 (71.3)
Age, m (s.d)	76.10 (8.9)	75.43 (9.1)	77.11 (5.9)	73.42 (4.3)
APOE e4 carrier	196	498	161	545
Female, n (%)	117 (59.7)	322 (64.7)	94 (58.4)	392 (68.3)
Age, m (s.d)	95.45 (8.9)	73.32 (9.0)	76.06 (5.9)	72.65 (4.3)

Table 2. Top-ranked GWAS result in the discovery, replication and meta-analysis.

Gene	Chr	Lead SNP (type)*	BP	m/M	MAF	Discovery (1,172/1,119)		Replication (976/980)		Meta-analysis		Previously reported GWAS			Alt Allele Frq [†]
						OR (95% CI)	P	OR (95% CI)	P	OR	P	GENE (SNP)	P	ref	
ALL samples															
APOE	19	rs429358 (m)	45411941	C/T	0.169	3.637 (3.03-4.37)	3.74×10 ⁻⁴³	2.608 (2.04-3.33)	1.89×10 ⁻¹⁴	3.227	5.90×10 ⁻⁵⁵	rs429358	1.4×10 ⁻⁵⁴⁶	[9]	0.036
TOMM40	19	rs10119 (3')	45406673	A/G	0.180	3.378 (2.83-4.03)	9.58×10 ⁻⁴²	2.230 (1.88-2.65)	7.49×10 ⁻²⁰	2.731	1.59×10 ⁻⁵⁷	rs10119	1.2×10 ⁻³⁴²	[36]	0.279
PVRL2	19	rs12972156 (i)	45387459	G/C	0.151	2.942 (2.45-3.54)	1.52×10 ⁻³⁰	2.656 (2.06-3.43)	5.42×10 ⁻¹⁴	2.841	8.30×10 ⁻⁴³	PVRL2 (rs412776)	2.2×10 ⁻²¹	[9]	0.001
APOC1	19	rs10414043 (g)	45415713	A/G	0.143	3.082 (2.55-3.73)	3.92×10 ⁻³¹	2.629 (2.02-3.43)	8.76×10 ⁻¹³	2.920	4.29×10 ⁻⁴²	rs10414043	1.2×10 ⁻⁵²²	[36]	0.109
APOE non-carrier															
CACNA1A	19	rs189753894 (i)	13624489	A/C	0.082	1.726 (1.34-2.23)	2.68×10 ⁻⁵	1.900 (1.35-2.67)	2.22×10 ⁻⁴	1.787	2.49×10⁻⁸	-	-	-	0.007
LRIG1	3	rs2280575 (i)	66542863	G/A	0.092	0.539 (0.41-0.71)	1.15×10 ⁻⁵	0.551 (0.40-0.76)	3.46×10 ⁻⁴	0.544	1.51×10⁻⁸	-	-	-	0.267
APOE e4 carrier															
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

*m: missense, s: synonymous, i: intronic, g: intergenic, 3': 3' UTR; [†]SNP alternative allele frequencies of Europeans reported in the allele frequency aggregator (ALFA) [37]

Figure 1. Gene expression of *CACNA1A* across different tissues (B) and expression quantitative trait loci (eQTL) analysis of rs2280575 in *LRIG1* (A). (A) The *CACNA1A* is expressed at a high level in the cerebellum (median TPM: 304.8) and in the cerebellar hemisphere (median TPM: 275.0). (B) Violin plot showing the effect of the eQTL rs2280575 on *LRIG1* expression in hypothalamus ($P = 1.13 \times 10^{-2}$). (Image available from <https://gtexportal.org/home/gene/CACNA1A>).